TrueAge Cellular Baseline

Product Overview

The TrueAge Cellular Baseline is a foundational epigenetic assessment available through EMIS+ in Singapore, designed to measure biological age at the molecular level using DNA methylation — the most validated epigenetic mechanism of cellular ageing. Unlike conventional blood biomarker panels, DNA methylation patterns across specific CpG loci change predictably and reproducibly with age, and deviations from expected methylation trajectories correlate with increased all-cause mortality, cardiometabolic disease burden, and functional decline. The test analyses over 900,000 CpG methylation sites to compute multiple validated biological age metrics, providing an objective and quantitative assessment of how rapidly an individual is ageing at the cellular level relative to chronological age.

The assessment employs the Illumina EPIC microarray platform within a CLIA-certified and HIPAA-compliant laboratory environment, ensuring analytical validity, chain-of-custody documentation, and data protection standards consistent with international clinical laboratory requirements. Results are interpreted via five established epigenetic clocks — GrimAge v2 (most predictive of all-cause mortality), PhenoAge (correlated with phenotypic age), Horvath v1 and v2 (pan-tissue clocks), and DunedinPACE (current pace of ageing) — alongside an immune cell composition report derived from methylation-based cell deconvolution. This multi-clock approach eliminates single-clock bias and enables nuanced longitudinal tracking of cellular ageing velocity over time.

Specifications

Clinical Indications and Applications

• Longevity medicine baseline: Establishing a quantitative epigenetic age baseline for individuals entering structured anti-ageing or longevity optimisation programmes, enabling objective tracking of cellular age response to interventions.
• Metabolic and cardiometabolic risk stratification: Identifying biological age acceleration in individuals with normal clinical markers but elevated epigenetic risk scores, particularly GrimAge discordance, which is independently predictive of cardiovascular events.
• Corporate preventive health programmes: Integration into executive health screening packages in Singapore where employers seek objective biological age data to complement conventional health screening panels.
• Post-intervention efficacy monitoring: Paired baseline and follow-up testing (recommended at 6–12 month intervals) to quantify cellular age response to caloric restriction, exercise protocols, metformin, NMN/NAD+ supplementation, or senolytics.
• Immune ageing and immunosenescence assessment: Methylation-based immune cell deconvolution to evaluate the ratio of naive to exhausted T-cell populations, relevant in oncology surveillance, post-COVID recovery programmes, and vaccine response evaluation.
• Pre-surgical and anaesthetic risk refinement: Supplementary biological age data for anaesthetists assessing frailty and physiological reserve in patients whose chronological age does not reflect functional status.

Frequently Asked Questions

Q: How does DNA methylation-based biological age differ from telomere length testing?
A: Telomere length testing measures the average length of chromosome end-caps and is subject to significant inter-cell variability and technical noise. DNA methylation clocks analyse specific CpG locus patterns across hundreds of thousands of genomic sites, providing a more reproducible and statistically robust measurement. GrimAge, in particular, has been validated in multiple prospective cohort studies as the strongest epigenetic predictor of all-cause mortality, outperforming telomere length and most conventional biomarkers for this application.

Q: What is the clinical significance of a biological age that exceeds chronological age?
A: Epigenetic age acceleration — where biological age is greater than chronological age — has been associated with increased risk of type 2 diabetes, cardiovascular disease, neurodegeneration, and all-cause mortality in meta-analyses involving hundreds of thousands of participants. A discordance of more than 3–5 years is generally considered clinically meaningful and warrants investigation of modifiable lifestyle, metabolic, and inflammatory factors. Practitioners should interpret results in the context of full clinical assessment rather than in isolation.

Q: How is the TrueAge Cellular Baseline conducted in Singapore?
A: The service is fulfilled through EMIS+ in Singapore. Following purchase, a collection kit is dispatched; the blood sample can be collected via a home dried-blood-spot kit or at a participating phlebotomy centre. Samples are shipped to the TruDiagnostic CLIA-certified laboratory in the United States, with results returned digitally via a secure portal within 4–6 weeks of sample receipt.

Q: Is this test registered with the Health Sciences Authority (HSA) Singapore?
A: The TrueAge Cellular Baseline is a wellness and longevity assessment service rather than an in vitro diagnostic (IVD) medical device as defined under the HSA Health Products (Medical Devices) Regulations 2010. It is not used for the diagnosis, monitoring, or treatment of a specific disease and therefore does not require product registration with HSA. Practitioners should communicate this distinction to patients, particularly in clinical contexts requiring regulatory-grade diagnostics.

Q: What is the recommended testing frequency for longitudinal tracking?
A: The consensus recommendation from longevity medicine practitioners and the scientific advisory board of TruDiagnostic is to retest at 6–12 month intervals following baseline assessment. This interval is aligned with the timescale over which meaningful epigenetic changes in response to lifestyle or pharmacological interventions are detectable. Shorter intervals may not capture biologically significant changes and are generally not recommended for routine monitoring.